Analgesics
Antiandrogens
Antihistamines
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
PPIs
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Abstract
All remdesivir studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19early.org COVID-19 treatment researchRemdesivirRemdesivir (more..)
Melatonin Meta
Metformin Meta
Antihistamines Meta
Azvudine Meta Molnupiravir Meta
Bromhexine Meta
Budesonide Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta PPIs Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   

The ‘very, very bad look' of remdesivir, the first FDA-approved COVID-19 drug

Cohen et al., Science, doi:10.1126/science.abf4549
Oct 2020  
  Post
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
Discussion of the controversial approval of remdesivir as the first FDA-approved drug for COVID-19 treatment in October 2020. Despite mixed results from clinical trials, including the large WHO Solidarity study that showed no significant benefits, the FDA approved remdesivir without consulting the external advisory committee. The European Union also agreed to a billion-dollar deal with the drug's manufacturer just before the disappointing WHO trial results were released, while the results were known to the manufacturer. Authors highlight concerns about the FDA's decision-making process, Gilead's aggressive marketing despite questionable efficacy, and the lack of transparency in both the FDA approval and EU procurement. Critics argue that the available data did not support such a strong endorsement of remdesivir, and that public discussion of the evidence would have been beneficial.
Cohen et al., 28 Oct 2020, preprint, 2 authors.
This PaperRemdesivirAll
{ 'indexed': {'date-parts': [[2024, 6, 11]], 'date-time': '2024-06-11T09:55:33Z', 'timestamp': 1718099733755}, 'reference-count': 0, 'publisher': 'American Association for the Advancement of Science (AAAS)', 'content-domain': {'domain': [], 'crossmark-restriction': False}, 'published-print': {'date-parts': [[2021, 3, 29]]}, 'DOI': '10.1126/science.abf4549', 'type': 'dataset', 'created': { 'date-parts': [[2020, 10, 29]], 'date-time': '2020-10-29T01:10:06Z', 'timestamp': 1603933806000}, 'source': 'Crossref', 'is-referenced-by-count': 9, 'title': "The ‘very, very bad look' of remdesivir, the first FDA-approved COVID-19 drug", 'prefix': '10.1126', 'member': '221', 'container-title': 'AAAS Articles DO Group', 'original-title': [], 'deposited': { 'date-parts': [[2023, 1, 30]], 'date-time': '2023-01-30T07:54:46Z', 'timestamp': 1675065286000}, 'score': 1, 'resource': { 'primary': { 'URL': 'https://www.science.org/content/article/very-very-bad-look-remdesivir-first-fda-approved-covid-19-drug'}}, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2021, 3, 29]]}, 'references-count': 0, 'URL': 'http://dx.doi.org/10.1126/science.abf4549', 'relation': {}, 'subject': [], 'published': {'date-parts': [[2021, 3, 29]]}}
Loading..
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit